SGLT2 inhibitors in kidney transplant recipients: metabolic changes, potassium-related safety and implications for albuminuria assessment
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are established therapies in chronic kidney disease (CKD), but comparative data in kidney transplant recipients (KTR) remain limited. Methods We retrospectively matched 100 KTR receiving SGLT2i to 100 controls not receiving SGLT2i and assessed body mass inde...